Gilead Sciences Stock To $192?

Our multi-factor assessment suggests that it may be time to buy more shares of GILD stock. We have, overall, a positive view of the stock, and a price of $192 may not be out of reach. We believe there are only a couple of things to fear in GILD stock given its overall Strong operating performance and financial condition. Considering stock’s Moderate valuation, we think it is Attractive.

Below is our assessment:

Ask yourself – Is holding GILD stock risky? Of course it is. High Quality Portfolio mitigates that risk.

Let’s get into details of each of the assessed factors but before that, for quick background: With $183 Bil in market cap, Gilead Sciences provides innovative medicines addressing unmet medical needs globally, specializing in HIV/AIDS treatments including Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, and Atripla.

[1] Valuation Looks Moderate

This table highlights how GILD is valued vs broader market. For more details see: GILD Valuation Ratios

[2] Growth Is Weak

• Gilead Sciences has seen its top line grow at an average rate of 2.6% over the last 3 years
• Its revenues have grown 2.4% from $29 Bil to $29 Bil in the last 12 months
• Also, its quarterly revenues grew 4.7% to $7.9 Bil in the most recent quarter from $7.6 Bil a year ago.

This table highlights how GILD is growing vs broader market. For more details see: GILD Revenue Comparison

[3] Profitability Appears Very Strong

• GILD last 12 month operating income was $12 Bil representing operating margin of 39.7%
• With cash flow margin of 34.0%, it generated nearly $10 Bil in operating cash flow over this period
• For the same period, GILD generated nearly $8.5 Bil in net income, suggesting net margin of about 28.9%

This table highlights how GILD profitability vs broader market. For more details see: GILD Operating Income Comparison

[4] Financial Stability Looks Very Strong

• GILD Debt was $25 Bil at the end of the most recent quarter, while its current Market Cap is $183 Bil. This implies Debt-to-Equity Ratio of 13.6%
• GILD Cash (including cash equivalents) makes up $9.6 Bil of $59 Bil in total Assets. This yields a Cash-to-Assets Ratio of 16.3%

[5] Downturn Resilience Is Strong

GILD has been more resilient than the S&P 500 index during various economic downturns. We assess this based on both (a) how much the stock fell and, (b) how quickly it recovered.

2022 Inflation Shock

• GILD stock fell 21.3% from a high of $73.64 on 29 December 2021 to $57.92 on 10 March 2022 vs. a peak-to-trough decline of 25.4% for the S&P 500.
• However, the stock fully recovered to its pre-Crisis peak by 28 October 2022
• Since then, the stock increased to a high of $155.80 on 11 February 2026 , and currently trades at $147.83

 
2020 Covid Pandemic

• GILD stock fell 32.6% from a high of $84.00 on 30 April 2020 to $56.65 on 30 December 2020 vs. a peak-to-trough decline of 33.9% for the S&P 500.
• However, the stock fully recovered to its pre-Crisis peak by 21 November 2022

 
2008 Global Financial Crisis

• GILD stock fell 34.4% from a high of $28.55 on 12 August 2008 to $18.73 on 10 October 2008 vs. a peak-to-trough decline of 56.8% for the S&P 500.
• However, the stock fully recovered to its pre-Crisis peak by 2 August 2012

The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.